Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants able to give voluntary informed consent before starting any study-related assessments or procedures (to be obtained/documented as per local regulations).
Adults (≥18 years of age) at time of informed consent.
Participants with at least 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3 (2018).
Participants with history of experiencing at least 3 migraine attacks per month with moderate to severe symptoms
Participants prescribed ubrogepant by investigator for the acute treatment of migraine according to local product label, independent of and prior to study participation
Participants willing and able to comply with the requirements of the study.
Participants with access to an electronic device (mobile phone, tablet, laptop, etc.) with internet access.
You may not be if
Participants previously exposed to a ubrogepant or rimegepant as routine therapy or through a clinical trial.
Participants with history of known contraindications to ubrogepant as per local labeling.
Participants Pregnant or planning to be pregnant or of childbearing potential not using contraception
Participants enrolled in any interventional studies that may include investigational compounds for migraine or non-AbbVie observational studies.
History or current evidence of any condition that might interfere with their ability to comply with the study requirements, in the opinion of the investigator.
